| Tremfya (guselkumab) / J&J |
2019-004230-42: Dose reduction of IL17 and IL23 inhibitors for psoriasis Dosis reductie van IL17 en IL23 remmers voor psoriasis |
|
|
| Not yet recruiting | 4 | 244 | Europe | secukinumab, ixekizumab, brodalumab, risankizumab, tildrakizumab, guselkumab, Injection, Cosentyx, Taltz, Kyntheum, Skyrizi, Ilumetri, Tremfya | Radboudumc, ZonMw, KCE | psoriasis psoriasis, psoriasis psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-000465-32: Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Srovnání guselkumabu s placebem v léčbě psoriatické artritidy s axiálním postižením u pacientů, kteří se zatím biologiky neléčili |
|
|
| Ongoing | 4 | 405 | RoW, Europe | guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Pharmaceutica N.V., Janssen Pharmaceutica, N.V. | Active Psoriatic Arthritis Axial Disease, Psoriasis Arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-004061-39: Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Patients With Moderate to Severe Plaque Psoriasis |
|
|
| Ongoing | 4 | 50 | Europe | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Pharmaceutica NV | Plaque Psoriasis, Psoriasis, Diseases [C] - Immune System Diseases [C20] | | | | |
ChiCTR2000041398: Effectiveness, safety and tolerance of guselkumab for the treatment of psoriasis in mainland China |
|
|
| Recruiting | 4 | 50 | | Guselkumab | Dermatology Hosipital of Southern Medical University; Dermatology Hosipital of Southern Medical University, Self-financing | psoriasis | | | | |
| Not yet recruiting | 4 | 50 | Europe | Solution for injection in pre-filled pen, Tremfya 100 mg solution for injection in pre-filled pen | Centre for Human Drug Research, Janssen-Cilag B.V. | Psoriasis, Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Active, not recruiting | 4 | 244 | Europe | Secukinumab, Cosentyx, Ixekizumab, Taltz, Brodalumab, Kyntheum, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumetri, Bimekizumab, Bimzelx | Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development, Belgium Health Care Knowledge Centre, University Hospital, Ghent | Psoriasis, Psoriasis Vulgaris | 12/25 | 12/25 | | |
| Terminated | 4 | 15 | Europe | Guselkumab | Janssen-Cilag Ltd., Janssen Pharmaceutica NV | Psoriasis | 07/23 | 07/23 | | |
NCT04914429: A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis |
|
|
| Completed | 4 | 327 | RoW | Guselkumab, TREMFYA, Placebo | Janssen Research & Development, LLC | Psoriasis | 09/23 | 09/23 | | |
| Completed | 4 | 79 | Europe | Venapuncture, Patient questionnaires | University Hospital, Ghent, KU Leuven, University Ghent | Psoriasis Vulgaris | 12/23 | 12/23 | | |
ChiCTR2200056656: A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter study to evaluate the efficacy and safety of guselkumab (TREMFYA?) in Chinese participants with moderate to severe plaque psoriasis |
|
|
| Recruiting | 4 | 150 | | receive Guselkumab 100 mg injection | The Second Hospital Affiliated to Zhejiang University School of Medicine; Johnson & Johnson (China) Investment Co., Ltd., Johnson & Johnson (China) Investment Co., Ltd. | Moderate-to-severe plaque psoriasis | | | | |
| Not yet recruiting | 4 | 210 | Europe | Proactive TDM-based dosing of secukinumab, Cosentyx, Proactive TDM-based dosing of ixekizumab, Taltz, Proactive TDM-based dosing of guselkumab, Tremfya | University Hospital, Ghent, Belgium Health Care Knowledge Centre | Psoriasis Vulgaris | 03/28 | 03/28 | | |
NCT05270733: Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics |
|
|
| Recruiting | 4 | 56 | US | Ustekinumab, Guselkumab, Risankizumab | University Hospitals Cleveland Medical Center, LEO Foundation, Case Western Reserve University | Psoriasis | 12/24 | 12/24 | | |
| Recruiting | 4 | 25 | US | Guselkumab | University of California, San Francisco, Janssen Biotech, Inc. | Psoriasis Guttate, Plaque Psoriasis | 01/25 | 01/25 | | |
| Recruiting | 4 | 350 | Canada, US | Guselkumab, Placebo | NYU Langone Health, Janssen Scientific Affairs, LLC | Psoriasis | 12/25 | 03/26 | | |
| Recruiting | 4 | 405 | Europe, Canada, US, RoW | Guselkumab, TREMFYA, Placebo | Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Janssen Pharmaceutica, N.V. | Arthritis, Psoriatic | 03/26 | 11/26 | | |
NCT05858632: Immune Spatial Features of Guselkumab Cutaneous Response |
|
|
| Recruiting | 4 | 10 | US | Guselkumab | University of California, San Francisco, Janssen Scientific Affairs, LLC | Psoriasis of Scalp | 06/26 | 06/26 | | |
ChiCTR2400087931: Exploration of Precision Individualized Medication Regimen for Psoriasis |
|
|
| Not yet recruiting | 4 | 278 | | Secukinumab Combined with Methotrexate Group; Guselkumab Combined with Methotrexate Group; Tildrakizumab Combined with Methotrexate Group; Ustekinumab Combined with Methotrexate Group; Ixekizumab Combined with Methotrexate Group | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, the National Key Research and Development Program of China (2023YFC2508103) | Psoriasis is a chronic inflammatory disease mediated by the immune system, influenced by both genetic and environmental factors. Clinically, it manifests as red papules or plaques with white scales. In severe cases, it can present with erythroderma or pustules, accompanied by fever and systemic pain. Besides affecting the skin, it can also cause damage to multiple organs, including nails, joints, | | | | |
2021-006282-37: Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Crohn’s Disease |
|
|
| Ongoing | 3 | 120 | Europe, RoW, Canada, Japan, US | Guselkumab, CNTO1959, Solution for infusion, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research & Development | Moderately to Severely Active Crohn’s Disease, Moderately to Severely Active Crohn’s Disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
2018-001238-16: A Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis |
|
|
| Not yet recruiting | 3 | 950 | Europe | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen-Cilag International N.V., Janssen-Cilag International NV, Janssen Pharmaceutica NV | Moderate to Severe Plaque Type Psoriasis, Psoriasis, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-001899-14: An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunosuppressive medication can be tapered without recurrence of symptoms |
|
|
| Not yet recruiting | 3 | 270 | Europe | Prednisolone p.o., Sulfasalazine, Leflunomide, Methotrexate p.o., Methotrexate s.c., Etanercept, Adalimumab, Infliximab, Abatacept s.c., Abatacept i.v., Tablet, Coated tablet, , Solution for injection, Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Solution for injection in dose-dispenser cartridge, Prolonged-release tablet, Xeljanz 5/10mg Filmtabletten, Otezla Filmtabletten, Simponi 50mg Injektionslösung Vorgefüllter Injektor/Fertigspritze, Cimzia 200mg Injektionslösung in einem Fertigpen, Orencia Injektionslösung in einer Fertigspritze, Orencia 250mg Pulver, Cosentyx 150mg Injektionslösung in einer Fertigspritze, Taltz, Cimzia 200mg Injektionslösung in einer Fertigspritze, Cimzia 200mg Injektionslösung in einer Patrone für ein Dosiergerät, Orencia 125mg Injektionslösung im Fertigpen, Cosentyx 150mg Injektionslösung in einem Fertigpen, Stelara 45mg/90mg Injektionslösung, Xeljanz 11mg Retardtablette, Rinvoq 15 mg Retardtablette, Tremfya 100mg Injektionslösung, Skyrizi 75/150mg Injektionslösung | Universitätsklinikum Erlangen, Universitätsklinikum Erlangen | Psoriatic arthritis Psoriasisarthritis, Psoriatic arthritis Gelenkbeteiligung bei Schuppenflechte, Diseases [C] - Immune System Diseases [C20] | | | | |
2020-004981-20: A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis |
|
|
| Ongoing | 3 | 950 | Europe, RoW | guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research & Development | Psoriatic arthritis (PsA), Psoriatic arthritis (PsA), Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000482-32: A Phase 3B, study of Guselkumab in Participants with ActivePsoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor α Agent |
|
|
| Ongoing | 3 | 450 | Europe | guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Pharmaceutica N.V. | Psoriatic Arthritis, Psoriatic Arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
GUIDE, NCT03818035: A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis |
|
|
| Active, not recruiting | 3 | 880 | Europe | Guselkumab, TREMFYA, Placebo Injection | Janssen-Cilag International NV | Psoriasis | 03/22 | 07/25 | | |
|
2020-006165-11: GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s Disease GRAVITI - Estudio de fase 3 para evaluar la eficacia y la seguridad del tratamiento de inducción con guselkumab subcutáneo en participantes con enfermedad de Crohn activa de grado moderado o severo |
|
|
| Ongoing | 3 | 318 | Europe, RoW | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development | Moderately to Severely Active Crohn's Disease Enfermedad de Crohn activa de grado moderado o severo, Inflammatory bowel disease (IBD) Enfermedad inflamatoria intestinal, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000491-10: FUZION - Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn’s Disease ÚÄinnost a bezpeÄnost pÅ™Ãpravku guselkumab u pacientů s fistulujÃcà formou perianálnà Crohnovy nemoci |
|
|
| Ongoing | 3 | 280 | RoW, Europe | Guselkumab, CNTO1959, Solution for infusion, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research & Development | Fistulizing perianal Crohn's Disease, Inflammatory bowel disease (IBD), Diseases [C] - Immune System Diseases [C20] | | | | |
2020-005503-40: Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis Estudio para evaluar la eficacia, farmacocinética, seguridad e inmunogenicidad del ustekinumab o guselkumab administrado por vía subcutánea en participantes pediátricos con artritis psoriásica juvenil activa |
|
|
| Ongoing | 3 | 80 | Europe, RoW, US | Ustekinumab, Guselkumab, CNTO1275, CNTO1959, Solution for injection, Solution for injection in pre-filled syringe, STELARA® | Janssen-Cilag International NV, Janssen Research & Development, LLC | Juvenile Psoriatic Arthritis Artritis Psoriásica Juvenil, Juvenile Psoriatic Arthritis Artritis Psoriásica Juvenil, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2022-000365-41: A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis Estudio de fase 3 para evaluar la eficacia y la seguridad del tratamiento de inducción con guselkumab subcutáneo en participantes con colitis ulcerosa activa de grado moderado a severo |
|
|
| Ongoing | 3 | 399 | Europe, RoW | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, Janssen Research & Development | Moderately to Severely Active Ulcerative Colitis Colitis ulcerosa activa de grado moderado a severo, Inflammatory bowel disease (IBD) Enfermedad inflamatoria intestinal (EII), Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 3 | 350 | Europe, Canada, Japan, US, RoW | Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Crohn Disease | 07/23 | 03/25 | | |
PROTOSTAR, NCT03451851 / 2017-003053-42: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants |
|
|
| Active, not recruiting | 3 | 120 | Europe, Canada, US, RoW | Guselkumab, CNTO1959, Placebo for guselkumab, Etanercept, Enbrel | Janssen Research & Development, LLC | Psoriasis | 07/23 | 12/26 | | |
PROGRESS, NCT05784129: A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection |
|
|
| Terminated | 3 | 4 | Europe, US | Guselkumab, CNTO1959, Placebo | Janssen Research & Development, LLC | Crohn's Disease | 09/23 | 10/23 | | |
2022-002389-33: Prevention of Recurrence post Operatively with Guselkumab Relative to Endoscopy and Symptoms Prevenzione delle recidive post operatorie con guselkumab in relazione all'endoscopia e ai sintomi |
|
|
| Not yet recruiting | 3 | 370 | Europe | Guselkumab, [CNTO1959], Solution for injection | JANSSEN CILAG INTERNATIONAL NV, Janssen-Cilag International NV, Janssen Research & Development | Crohn's Disease After Surgical Resection Malattia di Crohn dopo resezione chirurgica, Inflammatory bowel disease (IBD) Malattia infiammatoria dell'intestino, Diseases [C] - Immune System Diseases [C20] | | | | |
QUASAR Jr, NCT06260163: A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 120 | Europe, Japan, US, RoW | Guselkumab Subcutaneous, CNTO1959, TREMFYA, Guselkumab Intravenous | Janssen Research & Development, LLC | Colitis, Ulcerative | 05/28 | 08/28 | | |
NCT04397263: A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Active, not recruiting | 3 | 38 | Japan | Guselkumab, CNTO1959 | Janssen Pharmaceutical K.K. | Crohns Disease | 02/24 | 06/25 | | |
|
REASON, NCT06408935: Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients |
|
|
| Recruiting | 3 | 112 | RoW | Guselkumab, CNTO1959; TREMFYA | Janssen-Cilag Ltd. | Crohn's Disease | 06/27 | 08/28 | | |
| Active, not recruiting | 3 | 418 | Europe, Canada, Japan, US, RoW | Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Colitis, Ulcerative | 04/24 | 10/25 | | |
|
| Recruiting | 3 | 950 | Europe, Canada, US, RoW | Guselkumab, CNTO 1959, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Arthritis, Psoriatic | 01/25 | 12/27 | | |
| Recruiting | 3 | 280 | Europe, Canada, Japan, US, RoW | Guselkumab, CNTO1959, Placebo | Janssen-Cilag Ltd., Janssen Research & Development | Fistulizing Crohns Disease, Perianal Crohns Disease | 03/25 | 11/27 | | |
SPECTREM, NCT06039189: Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis |
|
|
| Active, not recruiting | 3 | 338 | Canada, US | Guselkumab, CNTO1959, Tremfya, Placebo | Janssen Research & Development, LLC | Moderate Plaque Psoriasis | 04/25 | 05/25 | | |
NCT05631457: Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (EVOLUTION) |
|
|
| Not yet recruiting | 3 | 300 | US | Guselkumab Prefilled Syringe [Tremfya], Tremfya, Golimumab, Simponi | University of Pennsylvania, Janssen Scientific Affairs, LLC | Psoriatic Arthritis | 05/25 | 05/25 | | |
VISIBLE, NCT05272150: Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis |
|
|
| Active, not recruiting | 3 | 213 | Canada, US | Guselkumab, CNTO1959, Tremfya, Placebo | Janssen Research & Development, LLC | Plaque Psoriasis, Scalp Psoriasis | 05/25 | 05/25 | | |
| Active, not recruiting | 3 | 453 | Europe, US, RoW | Guselkumab, Tremfya, CNTO1959, Placebo | Janssen Research & Development, LLC, Janssen Pharmaceutica N.V. | Arthritis, Psoriatic | 12/25 | 07/26 | | |
| Recruiting | 3 | 150 | US | Guselkumab, Tremfya, Golimumab, Simponi | University of Pennsylvania, Janssen Scientific Affairs, LLC | Psoriatic Arthritis | 05/26 | 05/26 | | |
| Recruiting | 3 | 60 | Europe, US, RoW | Ustekinumab, CNTO1275, STELARA, Guselkumab, CNTO1959, TREMFYA | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Arthritis, Juvenile | 11/26 | 08/27 | | |
| Recruiting | 3 | 120 | Europe, Japan, US, RoW | Guselkumab, CNTO1959, TREMFYA, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Crohn's Disease | 10/27 | 04/28 | | |
| Active, not recruiting | 2/3 | 1064 | Europe, Canada, Japan, US, RoW | Placebo, Guselkumab | Janssen Research & Development, LLC | Ulcerative Colitis | 09/23 | 10/27 | | |
|
|
|
|
|
| Active, not recruiting | 2/3 | 1409 | Europe, Canada, Japan, US, RoW | Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo | Janssen Research & Development, LLC | Crohn's Disease | 10/23 | 06/30 | | |
|
|
|
|
|
NCT05535738: Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation |
|
|
| Recruiting | 2/3 | 45 | US | Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy | John Harris | Skin Inflammation, Allergic Contact Dermatitis | 01/27 | 12/27 | | |
2017-003249-18: TIGERS study proposes to take mini fragments of synovial tissue to study the molecular patterns present in psoriatic arthritis, in order to to identify markers of disease progression and response to treatment with Ustekinumab, Guselkumab or Adalimumab to analyze and compare different expression patterns within synovial and cutaneous tissue , and to investigate whether molecular diagnosis allows to predict the evolution of the disease in the long term, as well as the therapeutic response. |
|
|
| Not yet recruiting | 2 | 36 | Europe | Ustekinumab, adalimumab, L04AC05, Powder and solvent for solution for injection, Solution for infusion, Solution for injection in pre-filled syringe, Tremfya 100 mg solution for injection in pre-filled syringe., STELARA® 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe, Humira 40 mg solution for injection in pre-filled syringe | Cliniques Universitaires Saint-Luc, Janssen Pharmaceutica | Psoriatic arthritis (PsA), Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-001048-70: Comparison of secukinumab versus guselkumab in clearing psoriatic plaques refractory to ustekinumab |
|
|
| Not yet recruiting | 2 | 40 | Europe | Secukinumab, Tremfya, AIN457, Solution for injection in pre-filled syringe, Solution for injection, Cosentyx, Tremfya | Novartis Pharma AG, Novartis Pharma AG | Plaque Psoriasis, Psoriasis looks like red, raised scaly areas of the skin, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-000622-26: A Proof-of-Concept Study of Guselkumab in the Treatment of Subjects with New-Onset or Relapsing Giant Cell Arteritis |
|
|
| Not yet recruiting | 2 | 60 | Europe | Guselkumab, CNTO1959, Solution for infusion, Solution for injection | Janssen-Cilag International N.V., JANSSEN CILAG INTERNATIONAL NV, Janssen Pharmaceutica N.V., Janssen Research R&D | Giant Cell Arteritis, Giant Cell Arteritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-004451-20: A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP) Multizentrische, offene, einarmige Pilotstudie zur Bewertung der Wirksamkeit und Sicherheit von Guselkumab bei Patienten mit mittelschwerer bis schwerer, palmoplantarer Pustulose (PPP) |
|
|
| Not yet recruiting | 2 | 50 | Europe | Guselkumab, CNTO 1959, Solution for injection in pre-filled syringe | Rheinische Friedrich-Wilhelms-Universität Bonn, Janssen-Cilag GmbH | Adult men and women with palmoplantar pustulosis Erwachsene männliche und weibliche Probanden mit palmoplantarer Pustulose, Adult men and women with palmoplantar pustulosis Erwachsene männliche und weibliche Probanden mit palmoplantarer Pustulose, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-000271-36: Immunotherapy with the bioactive substance Guselkumab in patients suffering from oral skin disease Lichen-Planus using an open-label, parallel, multi-center phase IIa trial design |
|
|
| Not yet recruiting | 2 | 45 | Europe | Guselkumab, Solution for infusion in pre-filled syringe, Tremfya | Philipps University Marburg, Janssen-Cilag GmbH | severe oral lichen planus (LP) with variable phenotype (erosive, ulcerating, hyperplastic/leucoplastic, and combined forms), severe oral skin disease lichen planus (LP) with variable outer appearance, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-002012-31: A Study of the Efficacy and Safety of Guselkumab and Golimumab in Participants with Active Psoriatic Arthritis Estudio para evaluar la eficacia y la seguridad de Guselkumab y Golimumab en pacientes con artritis psoriásica activa |
|
|
| Ongoing | 2 | 90 | Europe | guselkumab, golimumab, CNTO1959, CNTO148, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development | Active Psoriatic Arthritis Artritis Psoriásica Activa, Psoriatic Arthritis Artritis Psoriásica, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-001510-15: A Proof-of-concept Study of the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Not yet recruiting | 2 | 210 | Europe | Guselkumab, Golimumab, CNTO1959, CNTO148, Solution for infusion in pre-filled syringe, Solution for injection in pre-filled syringe, TREMFYA®, Simponi® | Janssen-Cilag International NV, Janssen Research & Development, LLC | Ulcerative Colitis, Inflammation of Digestive Tract, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT03975153: Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP) |
|
|
| Completed | 2 | 15 | US | guselkumab, Tremfya | Oregon Health and Science University | Pityriasis Rubra Pilaris | 08/22 | 03/24 | | |
2018-003155-38: A Study of the Efficacy and Safety of Guselkumab in Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | Europe | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe, TREMFYA | Janssen-Cilag International NV, Janssen Research & Development | Active Lupus Nephritis, Active Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Terminated | 2 | 33 | Europe, US, RoW | Guselkumab Dose 1, CNTO 1959, Placebo, Guselkumab Dose 2, CNTO1959, Standard-of-care treatment | Janssen Research & Development, LLC | Lupus Nephritis | 02/23 | 02/23 | | |
NCT04683029: A Study of Guselkumab in Participants With Systemic Sclerosis |
|
|
| Active, not recruiting | 2 | 56 | Japan | Guselkumab Dose 1, Guselkumab Dose 2, Placebo | Janssen Pharmaceutical K.K. | Scleroderma, Systemic | 05/23 | 07/24 | | |
THEIA, NCT04633447: A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis |
|
|
| Terminated | 2 | 53 | Europe, Canada, US, RoW | Guselkumab, Tremfya, CNTO 1959, Placebo | Janssen Research & Development, LLC | Giant Cell Arteritis | 05/24 | 05/24 | | |
| Completed | 2 | 91 | Europe, US, RoW | Guselkumab, TREMFYA, CNTO1959, Golimumab, SIMPONI, CNTO148, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Arthritis, Psoriatic | 05/24 | 08/24 | | |
| Active, not recruiting | 2 | 703 | Europe, Canada, Japan, US, RoW | Guselkumab, Golimumab, JNJ-78934804, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Crohn's Disease | 05/25 | 01/31 | | |
| Active, not recruiting | 2 | 577 | Europe, Canada, Japan, US, RoW | Guselkumab, Golimumab, JNJ-78934804, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Colitis, Ulcerative | 05/25 | 03/29 | | |
| Not yet recruiting | 2 | 17 | US | Guselkumab, Tremfya | Oregon Health and Science University, Janssen Scientific Affairs, LLC, Ohio State University | Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer | 08/27 | 08/27 | | |
NCT04736966: Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease |
|
|
| Completed | 1 | 13 | US | Guselkumab 30mg, Tremfya, Guselkumab 70mg, Guselkumab 100mg | University of California, San Diego | Alcoholic Liver Disease | 03/24 | 03/24 | | |
NCT04948398: Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis |
|
|
| No Longer Available | N/A | | NA | Guselkumab | Janssen Research & Development, LLC | Adenomatous Polyposis Coli | | | | |
| Recruiting | N/A | 50 | Europe | Guselkumab, Placebos | Centre for Human Drug Research, Netherlands, Janssen Pharmaceuticals | Psoriasis Vulgaris | 10/22 | 12/22 | | |
TIGERS, NCT04261010: TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_() Study |
|
|
| Completed | N/A | 36 | Europe | Global/single cell gene expression profiles obtained from Synovial biopsies | Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Janssen-Cilag International NV, University Hospital, Ghent | Psoriatic Arthritis | 09/23 | 09/23 | | |
GULLIVER, NCT04439526: A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis |
|
|
| Completed | N/A | 356 | Europe | Guselkumab, Tremfya | Janssen-Cilag S.p.A. | Psoriasis | 11/23 | 11/23 | | |
NCT06586281: Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy |
|
|
| Recruiting | N/A | 20 | US | Guselkumab, Tremfya | University of California, San Diego, Janssen Scientific Affairs, LLC | Psoriatic Arthritis | 09/26 | 12/26 | | |
NCT02103361: Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project |
|
|
| Recruiting | N/A | 200 | US | Ustekinumab, Stelara, Guselkumab, Tremfya | University of California, San Diego, The Organization of Teratology Information Specialists, Janssen Biotech, Inc. | Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease | 12/24 | 12/25 | | |
PsABIOnd, NCT05049798: A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice |
|
|
| Active, not recruiting | N/A | 1314 | Europe, Canada, Japan, RoW | Guselkumab, TREMFYA, IL-17i | Janssen Pharmaceutica N.V., Belgium | Arthritis, Psoriatic | 08/27 | 08/27 | | |
NCT05503875: Immunoclassification of Psoriasis: a Strategy for Precision Medicine |
|
|
| Recruiting | N/A | 100 | RoW | adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate | Second Affiliated Hospital, School of Medicine, Zhejiang University | Immunoclassification, Psoriasis | 12/27 | 12/27 | | |